GLP Watchdog

Best ED Telehealth Providers in 2026 — Ranked & Reviewed

What most online erectile dysfunction platforms actually sell is a compounded multi-ingredient product: sildenafil, tadalafil, or both together in a dissolvable troche or a chewable tablet. None of those is an FDA-approved single-agent therapy. Phase 3 trials and FDA review sit behind branded Cialis (tadalafil), Viagra (sildenafil), Levitra (vardenafil) and Stendra (avanafil), plus their FDA-approved generics, and behind nothing else. That does not make either path wrong. It makes the difference one of evidence and price. Every ED telehealth provider on the register is ranked below on price transparency, on drug formulary, on state availability, on pharmacy-partner disclosure, and on honest framing of FDA status. We also note where the care overlaps with GLP-1 weight-loss treatment, since losing weight improves erectile function in many men.

Lowest verified price: $171/mo1 provider compared

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed

1 ed telehealth providers compared · independently scored against our six-factor methodology.

Quick Picks: Top 1

#ProviderScore
1MyDrHankVisit
6weighted dimensions
1ed telehealth providers compared
Everychecked against the seller's own site
Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →

Detailed Reviews

1

MyDrHank

Verified partner

Best for: an oral route if you will not self-inject

6.9

This entry covers the erectile-dysfunction side of MyDrHank, whose legal name is Dr. Hank, LLC. Four products sit on the list: sildenafil in generic form, tadalafil both generic and daily, and MDH Drive, which dissolves rapidly and pairs sildenafil with tadalafil. Every case gets reviewed online by providers holding U.S. licenses, and three partner pharmacies are named. Plans are itemized at one, three and six months, the cheapest being $25/mo for generic sildenafil, with free shipping and nothing to commit to.

Score Breakdown

Value25%
5.3
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
5.5
Accessibility10%
5
Support10%
5

Pros

  • ✓Semaglutide costs $171 a month, 14% below the $199 median for oral semaglutide across the sellers we compare
  • ✓Tirzepatide costs $240 a month, close to the $250 median for compounded tirzepatide across the sellers we compare
  • ✓Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • ✓We found no FDA warning letters issued to MyDrHank
  • ✓Offers both oral and injectable options, so the format is your choice

Cons

  • ✗Confirm it serves your state before you start the intake
  • ✗Ask which pharmacy fills the prescription before you pay, so you can check its license
  • ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Starting from $25/moRead full review →
Visit MyDrHank →

Reading an online ED offer

Compounded multi-ingredient troches and chewables, built on sildenafil or tadalafil, are what most online ED platforms actually sell. FDA-approved single-agent tablets are a different product. Buying either one is defensible. Not knowing which one is in the box is not.

What to check

  • Single agent, or a compounded combination. Phase 3 trials studied generic sildenafil and tadalafil at defined doses, and both hold FDA approval. Compounded troches and chewables carry the same molecules in combinations no trial has tested. That is a different evidence position rather than a disqualifying one.
  • The fulfillment pharmacy, named. Where the product is compounded, the pharmacy filling it can be named, and once named it can be traced through its state Board of Pharmacy. A reference to a 'partner pharmacy network', with no name attached, leaves nothing to trace.
  • Cardiac questions in the intake. ED that appears suddenly and for no obvious reason can be an early cardiovascular marker. PDE5 inhibitors are also contraindicated alongside nitrates. An intake asking about cardiac history and current medications is practicing medicine. One asking only for a shipping address is taking an order.

Red flags

  • Neither pharmacy nor licensing disclosed. The 503A or 503B pharmacy behind a compounded ED product is something a seller can state plainly, and many do. Where a site offers 'our pharmacy network' and stops there, the contents of the box stay unverified.
  • A compounded product described as approved. No compounded sildenafil or tadalafil combination holds FDA approval, and none has run the pivotal trials at the doses being sold. Marketing that positions such a product as the equivalent of Viagra or Cialis, without stating the difference, misleads by construction.
  • Nitrates and cardiac history never asked about. Combining a PDE5 inhibitor with a nitrate is dangerous, and prescribing straight past new-onset ED can bury the cardiac workup it may call for. An intake carrying neither question has dropped a safety step and called the result convenience.
  • The tier you join is not the tier you stay on. Entry tiers here are priced low, and the step up to a standard or high-frequency tier is often steep enough to double the monthly figure. What a platform charges on an ongoing basis is the number that counts.

Every seller listed above is scored on these criteria under our six-dimension methodology, with prices re-checked against the seller’s own live site.

How we rank, and what counts as “legit”

Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.

Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].

How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Frequently Asked Questions

Legal, yes, where a state-licensed 503A or 503B compounding pharmacy prepares them against a valid patient-specific prescription. Sildenafil and tadalafil, the active ingredients, are well-studied molecules carrying decades of post-marketing safety data. The multi-ingredient combinations are a different matter: not FDA-approved, never taken through Phase 3 trials at the exact combinations being sold, and not bioequivalent to Viagra or Cialis as branded. A legitimate provider states that outright instead of implying equivalence.
Rarely. For the standard ED indication, sildenafil and tadalafil go uncovered by commercial insurance, by Medicare Part D and by most Medicaid programs, because the therapy is generally treated as quality-of-life rather than medically necessary. For most patients, then, comparing telehealth providers is the same thing as comparing out-of-pocket cost.
In a meaningful fraction of obese men, yes. In obese men with ED, trial data on structured weight-loss interventions found a sustained ~15 kg loss restoring normal erectile function for roughly a third of participants, where only a small fraction of controls recovered. Where a patient has a BMI of 30 or higher along with ED, weight loss, GLP-1 medications included, is legitimate first-line or co-treatment rather than a vague suggestion about lifestyle.
Six weighted dimensions produce the score. Value (25%) and Effectiveness (25%) carry the most, then User Experience (15%) and Trust & Safety (15%), then Accessibility (10%) and Support (10%). Behind them sits our research into pricing data, clinical evidence, user reviews and publicly available information. Those weights then combine into one overall score out of 10.
The six-dimension methodology computes each score on its own, and no commercial relationship ever moves a provider's underlying number. Every provider's full score sits on its card for you to check. Some providers do hold affiliate agreements with us, which means a commission reaches us if you click through and buy. On the lists carrying the highest commercial intent — the weight-loss injection and shot lists, the semaglutide and tirzepatide lists, the compounded and cheapest molecule lists, and the fitness-app list, plus the rankings we run for ED telehealth, TRT clinics and HRT providers — affiliate partners take the top positions. Every other list runs in score order, or in price order on the cheapest lists. That placement is disclosed here, on our methodology page, and on our affiliate-disclosure page.
Sources & methodology — as of September 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings